Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

CNX-013-B2, a unique pan tissue acting rexinoid, modulates several nuclear receptors and controls multiple risk factors of the metabolic syndrome without risk of hypertriglyceridemia, hepatomegaly and body weight gain in animal models.

Sadasivuni MK, Reddy BM, Singh J, Anup MO, Sunil V, Lakshmi MN, Yogeshwari S, Chacko SK, Pooja TL, Dandu A, Harish C, Gopala AS, Pratibha S, Naveenkumar BS, Pallavi PM, Verma MK, Moolemath Y, Somesh BP, Venkataranganna MV, Jagannath MR.

Diabetol Metab Syndr. 2014 Aug 12;6(1):83. doi: 10.1186/1758-5996-6-83. eCollection 2014.

2.

A novel 11β-hydroxysteroid dehydrogenase type1 inhibitor CNX-010-49 improves hyperglycemia, lipid profile and reduces body weight in diet induced obese C57B6/J mice with a potential to provide cardio protective benefits.

Anil TM, Dandu A, Harsha K, Singh J, Shree N, Kumar VS, Lakshmi MN, Sunil V, Harish C, Balamurali GV, Naveen Kumar BS, Gopala AS, Pratibha S, Sadasivuni M, Anup MO, Moolemath Y, Venkataranganna MV, Jagannath MR, Somesh BP.

BMC Pharmacol Toxicol. 2014 Aug 7;15:43. doi: 10.1186/2050-6511-15-43.

3.

CNX-011-67, a novel GPR40 agonist, enhances glucose responsiveness, insulin secretion and islet insulin content in n-STZ rats and in islets from type 2 diabetic patients.

Sunil V, Verma MK, Oommen AM, Sadasivuni M, Singh J, Vijayraghav DN, Chandravanshi B, Shetty J, Biswas S, Dandu A, Moolemath Y, Venkataranganna MV, Somesh BP, Jagannath MR.

BMC Pharmacol Toxicol. 2014 Mar 25;15:19. doi: 10.1186/2050-6511-15-19.

4.

Treatment with CNX-011-67, a novel GPR40 agonist, delays onset and progression of diabetes and improves beta cell preservation and function in male ZDF rats.

Gowda N, Dandu A, Singh J, Biswas S, Raghav V, Lakshmi MN, Shilpa PC, Sunil V, Reddy A, Sadasivuni M, Aparna K, Verma MK, Moolemath Y, Anup MO, Venkataranganna MV, Somesh BP, Jagannath MR.

BMC Pharmacol Toxicol. 2013 May 21;14:28. doi: 10.1186/2050-6511-14-28.

Supplemental Content

Support Center